This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_KIDNEY_PAPILLARYADENO_EXALLC for full statistics.
Adenocarcinoma and Papillary adenocarcinoma of kidney
C3_KIDNEY_PAPILLARYADENO
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
345 |
4. Check minimum number of eventsNone |
345 |
5. Include endpointsNone |
345 |
6. Filter based on genotype QC (FinnGen only) |
345 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Adenocarcinoma and Papillary adenocarcinoma of kidney
based on the number of shared cases.
Similar with more cases:
- Adenocarcinoma and Papillary adenocarcinoma of kidney, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of kidney, except renal pelvis
- Malignant neoplasm of urinary organs
- Malignant neoplasm of kidney, except renal pelvis, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of urinary organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 345 | 83 | 262 |
| Unadjusted period prevalence (%) | 0.09 | 0.03 | 0.12 |
| Median age at first event (years) | 67.04 | 67.58 | 66.87 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 322
- Matched controls
- 3218
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
3045.4
323.0
311
29
8260/3-C64.9
ICD-O-3
Papillary adenocarcinoma, NOS, of kidney, NOS
+∞
323.0
322
*
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
415.9
299.5
267
37
KAD00
NOMESCO Finland
Partial nephrectomy
188.4
83.6
84
6
KAD01
NOMESCO Finland
Percutaneous endoscopic partial nephrectomy
302.2
72.5
71
*
B01AB10
ATC
tinzaparin; parenteral
13.8
58.9
109
115
KAC10
NOMESCO Finland
Total nephrectomy with capsule
97.3
58.4
63
8
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
39.6
50.9
64
20
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
82.5
49.9
55
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.9
49.5
132
259
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
11.7
44.2
87
99
WX408
NOMESCO Finland
General anesthesy, balanced
4.7
35.8
168
603
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
52.0
31.3
37
8
KA1AE
NOMESCO Finland
Kidney ultrasound examination
14.2
30.6
53
44
JN4AD
NOMESCO Finland
Body CT examination
6.4
28.3
82
164
TPH07
NOMESCO Finland
Cathetrisation of artery
5.4
27.6
94
229
WX302
NOMESCO Finland
Thoracal epidural anesthesy
7.7
26.9
66
104
JN4CD
NOMESCO Finland
Very extensive body CT
9.4
26.6
57
72
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
25.6
213
1142
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
7.0
25.2
66
114
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
9.1
23.6
51
65
JN4BD
NOMESCO Finland
Extensive body CT
4.7
23.5
91
250
N02AX02
ATC
tramadol; systemic, rectal
3.3
22.4
197
1051
JN3AD
NOMESCO Finland
Abdominal CT examination
5.9
21.7
65
133
R4110
NOMESCO Finland
Physiotherapy
3.4
21.3
136
569
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
11.1
18.9
36
36
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.1
18.7
34
31
WX402
NOMESCO Finland
General anaesthesia
3.6
17.6
90
310
205
Kela drug reimbursment
Chronic hypertension
2.8
16.7
149
752
B01AB05
ATC
enoxaparin; parenteral
2.8
16.6
147
739
N02BE01
ATC
paracetamol; systemic, rectal
4.2
15.2
297
2372
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
33.5
15.0
19
6
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
26.5
14.9
20
8
A12AA04
ATC
calcium carbonate; oral
13.4
14.6
25
20
N18.8
ICD-10 Finland
Other chronic renal failure
7.1
14.6
36
56
197
Kela drug reimbursment
Sunitinib
38.0
14.6
18
5
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
6.6
14.3
37
62
U14
ICPC
Kidney symptom/complaint
11.2
14.0
26
25
Z49.1
ICD-10 Finland
Extracorporeal dialysis
21.2
14.0
20
10
N28.1
ICD-10 Finland
Cyst of kidney
14.5
13.9
23
17
A11CC03
ATC
alfacalcidol; systemic
8.6
13.9
30
38
V03AE01
ATC
polystyrene sulfonate; oral
22.3
13.5
19
9
L01XE04
ATC
[U] sunitinib; oral
42.0
13.3
16
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
17.7
13.2
20
12
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
9.1
13.1
27
32
TK800
NOMESCO Finland
Hemodialysis
7.9
12.8
29
40
196
Kela drug reimbursment
Paricalcitol and cinacalcet
135.1
12.5
13
*
Z94.0
ICD-10 Finland
Kidney transplant status
15.1
12.4
20
14
U75
ICPC
Malignant neoplasm of kidney
22.3
12.1
17
8
KA3LT
NOMESCO Finland
Njurlesion coagulation
67.5
11.7
13
*
KAC00
NOMESCO Finland
Nephrectomy
67.5
11.7
13
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
23.9
11.7
16
7
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.9
11.6
81
335
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.1
11.6
46
125
B03XA02
ATC
darbepoetin alfa; parenteral
9.4
11.0
22
25
137
Kela drug reimbursment
Uraemia requiring dialysis
18.6
10.8
16
9
H05BX01
ATC
cinacalcet; oral
22.4
10.8
15
7
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
22.4
10.8
15
7
C08CA01
ATC
amlodipine; oral
2.2
10.8
162
1004
127
Kela drug reimbursment
Transplant complication
10.6
10.7
20
20
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.1
10.5
62
229
N18.0
ICD-10 Finland
End-stage renal disease
16.8
10.5
16
10
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.3
10.2
38
97
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
2.6
10.0
79
353
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
56.7
9.7
11
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
18.2
9.5
14
8
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.5
9.5
45
143
KAC01
NOMESCO Finland
Percutaneous endoscopic nephrectomy
102.9
9.5
10
*
1502
Kela drug reimbursment
Cabozantinib
+∞
9.4
9
*
I10
ICD-10 Finland
Essential (primary) hypertension
2.1
9.1
226
1690
JN3KE
NOMESCO Finland
Abdominal ultrasound with added contrast
19.3
9.0
13
7
M04AA01
ATC
allopurinol; systemic
2.5
9.0
75
344
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
13.0
9.0
15
12
ZXA05
NOMESCO Finland
Left side
2.2
8.5
100
543
KA3CT
NOMESCO Finland
Biopsy of kidney under CT guidance
92.4
8.5
9
*
WX110
NOMESCO Finland
Local anesthesy
2.0
8.4
219
1642
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
11.2
8.4
15
14
KB1CG
NOMESCO Finland
Extensive MRI examination of urinary tract with high intensity magnet
+∞
8.4
8
*
S18
ICPC
Laceration/cut
2.0
8.1
157
1041
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
34.3
8.1
10
*
UKC02
NOMESCO Finland
Cystoscopy
2.3
8.0
86
442
J01MA02
ATC
ciprofloxacin; systemic
2.0
8.0
147
954
L04AA06
ATC
mycophenolic acid; systemic
8.1
8.0
17
22
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.5
7.8
36
112
B05DA
ATC
Isotonic solutions
15.5
7.8
12
8
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
15.5
7.8
12
8
158
Kela drug reimbursment
Everolimus
46.1
7.7
9
*
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
18.9
7.7
11
6
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
12.3
7.6
13
11
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
25.7
7.6
10
*
130
Kela drug reimbursment
Malignant tumour
2.8
7.4
49
194
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
7.4
84
445
KH1BD
NOMESCO Finland
Extensive urinary tract CT examination
11.2
7.4
13
12
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
9.7
7.4
14
15
3012
Kela drug reimbursment
Cabozantinib
+∞
7.3
7
*
C08CA02
ATC
felodipine; oral
2.7
7.3
52
216
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.3
7.2
71
349
V03AE02
ATC
sevelamer; oral
20.6
7.2
10
5
C09AA02
ATC
enalapril; systemic
2.1
6.9
88
485
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
14.2
6.9
11
8
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
40.9
6.8
8
*
C02AC05
ATC
moxonidine; oral
3.3
6.7
32
103
N02AJ06
ATC
codeine and paracetamol; systemic
1.9
6.7
123
784
R31
ICD-10 Finland
Unspecified haematuria
2.4
6.6
56
255
L04AA01
ATC
[U] ciclosporin; systemic
9.0
6.6
13
15
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
10.3
6.6
12
12
ZXA00
NOMESCO Finland
Right side
2.0
6.6
102
610
C03CA01
ATC
furosemide; systemic
2.0
6.5
106
643
Z49.2
ICD-10 Finland
Other dialysis
14.7
6.4
10
7
KB1DG
NOMESCO Finland
Very extensive MRI of urinary tract
+∞
6.3
6
*
L01XE26
ATC
[U] cabozantinib; oral
+∞
6.3
6
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
6.2
102
621
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.9
6.1
106
662
C08CA13
ATC
lercanidipine; oral
2.3
6.0
57
273
GD1AD
NOMESCO Finland
Thorax CT examination
3.5
6.0
26
78
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
235
1172
4.15
34.91
6.2
3.3
—
—
—
0
0
106
303
4.61
34.80
12.9
7.9
12.4
10.4
mmol/l
2.12
100
286
88
219
5.05
34.26
9.2
4.1
162.2
89.2
ng/l
4.30
81
196
251
1393
3.94
29.95
5.0
4.3
—
—
—
0
0
192
901
3.55
29.82
6.0
3.2
0.2
0.5
e6/l
1.99
170
688
244
1339
3.81
29.40
9.1
5.5
34.8
34.9
g/l
0.13
226
1254
75
186
4.87
29.02
9.5
12.7
23.0
24.6
mmol/l
7.34
75
175
166
724
3.49
28.75
2.8
2.6
—
—
—
0
0
123
447
3.72
28.25
15.1
6.0
1.1
1.0
mmol/l
2.52
117
412
121
455
3.56
26.10
10.2
8.0
104.5
104.0
mmol/l
0.73
121
441
131
525
3.41
25.44
4.9
3.1
0.8
1.5
e6/l
0.97
79
302
242
1402
3.43
25.01
15.3
6.9
1.2
1.2
mmol/l
0.05
227
1276
132
549
3.27
23.88
4.6
2.9
0.4
1.0
e6/l
2.79
80
323
311
2277
4.71
19.13
12.6
8.8
80.8
80.0
u/l
0.13
300
2137
105
428
3.09
19.08
10.2
8.6
-1.1
1.3
mmol/l
9.37
93
331
238
1520
2.82
17.85
17.1
7.8
1.2
1.2
mmol/l
0.08
205
1296
155
875
2.40
13.96
4.3
2.9
389.2
6107.6
umol/l
3.25
138
751
259
1842
2.63
13.75
8.1
5.5
6.7
6.8
mmol/l
0.41
252
1746
238
1675
2.36
12.16
10.0
10.0
4.7
4.2
e9/l
1.50
203
1478
95
453
2.51
12.15
6.5
2.4
20.9
23.0
%
0.86
81
390
165
1003
2.24
12.01
5.0
4.0
2.4
2.3
mmol/l
0.92
143
868
97
473
2.46
11.78
6.3
2.4
2.2
2.3
g/l
0.61
89
433
109
572
2.32
11.15
3.7
3.7
2.5
2.5
mmol/l
0.62
90
499
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
38
120
3.43
10.21
1.9
2.4
0.3
0.4
u/ml
0.21
12
59
71
319
2.54
10.14
8.0
4.0
1.1
2.1
mmol/l
2.00
63
248
71
320
2.53
10.07
8.0
4.1
5.8
5.8
kpa
0.11
71
308
97
517
2.22
9.35
6.4
2.4
10.9
12.8
umol/l
2.01
90
477
219
1600
2.01
8.72
8.4
7.6
10.5
12.5
umol/l
2.11
208
1525
157
1065
1.87
7.39
5.8
4.1
24.2
9.0
mg/mmol
2.84
120
684
264
2125
2.03
7.21
5.5
4.3
17.4
12.9
mm/h
2.54
241
1949
38
159
2.56
6.21
1.9
1.9
2.0
1.5
g/l
1.47
31
137
319
2821
2.74
6.10
28.0
17.1
37.9
27.2
mg/l
4.50
291
2310
90
543
1.89
5.89
4.4
3.6
0.8
0.8
mmol/l
0.22
85
512
46
220
2.26
5.62
4.6
2.9
41.4
60.6
ml/min/173m2
3.91
29
97
152
1091
1.70
5.44
3.3
2.2
80.5
77.1
nmol/l
0.69
135
956
8
5
16.32
5.43
8.8
4.6
5.6
7.2
mmol/l
—
8
5
32
132
2.57
5.39
2.3
3.1
—
—
—
0
0
52
270
2.09
5.18
5.4
3.0
5.1
4.4
kpa
1.63
52
258
156
1139
1.67
5.16
5.4
2.6
211.4
174.0
ug/l
0.57
149
1035
98
634
1.76
5.03
4.3
4.0
242.1
366.7
ng/l
0.30
88
544
134
949
1.67
4.93
3.1
2.7
61.2
56.6
u/l
0.84
121
886
15
42
3.69
4.82
1.3
1.2
—
—
—
0
0
182
1404
1.63
4.71
4.6
3.7
0.0
0.0
estimate
0.00
39
266
86
550
1.75
4.54
2.2
1.9
—
—
—
0
0
16
49
3.38
4.52
2.9
3.0
—
829.5
—
0
6
12
30
4.11
4.47
1.0
1.1
—
—
—
0
0
40
201
2.12
4.33
2.1
1.6
—
—
—
0
0
21
79
2.77
4.24
1.7
1.2
—
—
—
0
0
181
1423
1.57
4.13
4.8
3.7
0.0
0.0
estimate
0.00
39
253
111
783
1.62
4.00
2.5
2.0
3.3
3.1
mg/l
0.25
98
680
178
1403
1.56
3.96
6.2
5.0
0.0
0.0
estimate
0.00
39
266
284
2507
1.75
3.86
33.5
18.0
38.3
40.1
%
2.61
204
1671
325
3005
2.41
3.75
38.0
20.0
139.1
139.6
mmol/l
3.12
316
2931
17
61
2.88
3.74
1.4
1.4
—
—
—
0
0
17
61
2.88
3.74
1.4
1.4
—
—
—
0
0
164
1288
1.52
3.60
2.2
2.0
97.3
92.6
pmol/l
0.41
84
679
325
3015
2.34
3.54
38.6
20.2
4.1
4.0
mmol/l
5.72
316
2942
12
36
3.42
3.51
3.7
2.7
—
—
—
0
0
38
205
1.96
3.42
5.2
3.7
0.5
1.9
mmol/l
1.68
30
163
54
327
1.77
3.40
4.7
3.4
—
—
—
0
0
61
384
1.71
3.36
2.1
1.9
—
—
—
0
0
61
388
1.70
3.24
2.2
1.9
—
—
—
0
0
11
33
3.41
3.22
5.0
2.4
—
—
—
0
0
27
135
2.08
3.00
6.1
4.3
24.3
25.2
mmol/l
0.67
21
127
17
70
2.50
2.92
1.1
1.3
—
—
—
0
0
21
96
2.26
2.90
1.2
1.3
—
—
—
0
0
37
210
1.85
2.88
1.6
1.7
—
—
—
0
0
297
2713
1.68
2.84
29.1
15.8
62.0
77.3
ml/min/173m2
19.27
275
2285
31
171
1.89
2.64
4.9
2.9
1.2
1.2
%
0.10
31
171
35
202
1.82
2.60
1.3
1.4
—
—
—
0
0
6
12
5.07
2.41
1.0
1.5
—
—
—
0
0
6
12
5.07
2.41
1.0
1.5
—
—
—
0
0
8
22
3.70
2.38
1.1
1.1
—
—
—
0
0
207
1789
1.39
2.34
5.1
5.2
2.2
2.7
ug/l
1.03
195
1601
14
59
2.43
2.32
3.2
1.4
—
—
—
0
0
9
28
3.27
2.32
1.3
1.2
—
—
—
0
0
130
1041
1.40
2.31
2.9
3.2
2707.7
1474.5
ng/l
0.87
115
904
130
1042
1.40
2.30
3.2
3.1
0.8
0.8
ug/l
0.15
105
713
14
60
2.39
2.25
1.6
1.2
—
—
—
0
0
101
778
1.42
2.23
1.9
1.5
19.3
20.4
nmol/l
0.29
95
656
53
359
1.56
2.20
3.5
5.0
3.2
28.4
ug/l
1.21
44
305
53
360
1.56
2.17
2.4
3.2
7.7
10.8
umol/l
0.58
46
321
19
98
1.99
1.99
2.4
1.6
—
—
—
0
0
210
1853
1.34
1.89
3.5
3.3
48.3
55.9
u/l
1.00
193
1722
83
637
1.40
1.85
1.5
1.7
1.2
1.4
mg/l
0.36
64
506
21
116
1.86
1.83
1.6
1.7
—
—
—
0
0
319
3034
1.68
1.80
15.6
11.7
24.9
27.2
u/l
2.28
305
2923
8
30
2.71
1.73
1.0
1.4
—
—
—
0
0
14
68
2.10
1.72
2.3
2.8
17.1
15.7
%
—
7
33
15
75
2.05
1.72
1.2
1.5
—
—
—
0
0
22
129
1.75
1.61
2.4
1.9
—
—
—
0
0
6
20
3.03
1.58
1.5
1.2
—
—
—
0
0
12
58
2.11
1.51
1.5
1.5
—
—
—
0
0
9
37
2.47
1.49
1.1
2.2
—
—
—
0
0
11
52
2.15
1.46
1.2
1.8
—
—
—
0
0
17
95
1.83
1.46
1.5
1.5
—
—
—
0
0
218
1973
1.29
1.44
4.2
3.4
14.9
15.0
pmol/l
0.13
192
1737
9
39
2.34
1.44
1.1
2.1
—
—
—
0
0
9
39
2.34
1.44
3.2
3.7
—
—
—
0
0
268
2503
1.32
1.32
4.9
4.2
2.2
2.0
mu/l
0.42
242
2233
19
114
1.71
1.31
2.3
1.7
—
—
—
0
0
15
84
1.82
1.29
1.3
1.8
—
—
—
0
0
5
18
2.80
1.29
1.0
1.1
—
—
—
0
0
18
107
1.72
1.28
3.8
2.4
215.5
79.9
ug/min
0.50
13
58
21
131
1.64
1.26
1.7
1.8
—
—
—
0
0
15
85
1.80
1.25
1.5
1.6
—
—
—
0
0
163
1442
1.25
1.24
4.4
4.5
24.1
20.9
%
1.74
90
705
24
156
1.58
1.24
2.5
2.1
0.4
3.3
ug/l
0.91
18
136
11
56
2.00
1.23
1.1
2.0
—
—
—
0
0
8
37
2.19
1.22
1.3
1.9
—
—
—
0
0
8
37
2.19
1.22
1.3
1.9
—
—
—
0
0
8
37
2.19
1.22
1.3
1.9
—
—
—
0
0
5
19
2.65
1.22
1.4
2.2
—
—
—
0
0
5
19
2.65
1.22
1.4
2.2
—
—
—
0
0
5
19
2.65
1.22
1.4
2.2
—
—
—
0
0
5
19
2.65
1.22
1.4
2.2
—
—
—
0
0
15
86
1.78
1.21
1.4
1.8
—
—
—
0
0
21
136
1.58
1.11
2.6
3.2
—
—
—
0
0
13
75
1.76
1.04
2.9
2.6
7.8
7.9
kpa
0.03
13
66
63
507
1.30
1.04
1.3
1.2
1.7
1.2
u/ml
0.19
13
140
11
60
1.86
1.04
1.3
1.7
—
—
—
0
0
96
815
1.25
1.03
1.8
1.7
1.6
1.3
mmol/l
2.11
86
673
16
99
1.65
1.02
1.1
1.0
—
—
—
0
0
16
99
1.65
1.02
1.6
2.2
4.5
3.8
g/l
0.85
16
92
58
465
1.30
0.99
41.4
25.3
1.2
1.3
inr
—
8
61
12
70
1.74
0.93
1.2
1.7
—
—
—
0
0
12
71
1.72
0.90
1.1
1.5
—
—
—
0
0
72
601
1.25
0.90
1.9
1.7
1510.7
1190.4
nmol/l
0.64
52
458
48
381
1.30
0.89
5.0
4.9
29.9
31.5
%
0.49
33
251
10
56
1.81
0.88
1.1
1.7
—
—
—
0
0
40
311
1.32
0.86
1.2
1.3
—
—
—
0
0
11
65
1.72
0.83
1.3
1.3
11.0
5.9
u/l
0.54
11
53
291
2803
1.24
0.75
5.3
5.0
6.2
6.1
mmol/l
0.10
255
2539
5
24
2.10
0.75
1.4
1.1
—
—
—
0
0
39
310
1.29
0.73
2.7
2.6
5.9
8.8
ug/l
0.91
34
282
7
39
1.81
0.73
3.3
2.8
—
34.4
—
0
9
299
2893
1.25
0.70
5.7
5.4
2.4
2.6
mmol/l
2.39
267
2632
293
2829
1.24
0.70
5.1
4.8
4.3
4.4
mmol/l
1.44
260
2593
18
127
1.44
0.69
1.9
2.1
34.9
38.3
u/l
0.24
18
114
17
119
1.45
0.68
1.2
1.2
103.4
114.8
iu/ml
—
5
34
160
1476
1.16
0.66
3.0
2.4
—
—
—
0
0
122
1106
1.16
0.63
4.8
3.9
—
—
—
0
0
284
2743
1.20
0.62
7.6
6.4
40.7
40.9
mmol/mol
0.10
255
2533
13
88
1.50
0.61
3.1
2.7
23.2
25.0
mmol/l
1.24
13
74
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.7
—
—
—
0
0
136
1251
1.14
0.57
4.2
4.0
44.8
50.2
ng/l
0.17
102
956
6
37
1.63
0.56
1.0
1.6
—
—
—
0
0
44
370
1.22
0.54
13.0
8.6
—
—
—
0
0
6
39
1.55
0.53
1.0
1.6
—
—
—
0
0
6
39
1.55
0.53
1.0
1.6
—
—
—
0
0
6
39
1.55
0.53
1.0
1.6
—
—
—
0
0
6
40
1.51
0.52
1.0
1.6
—
—
—
0
0
6
40
1.51
0.52
1.0
1.6
—
—
—
0
0
12
84
1.44
0.50
1.5
1.3
—
—
—
0
0
7
46
1.53
0.48
1.0
1.7
—
—
—
0
0
33
395
0.82
0.48
1.2
1.3
34.5
10.1
u/ml
—
9
139
11
79
1.41
0.41
1.2
2.4
—
—
—
0
0
8
59
1.36
0.41
1.0
1.2
—
—
—
0
0
280
2731
1.13
0.38
4.5
4.3
1.5
1.3
mmol/l
3.33
238
2475
288
2814
1.14
0.38
5.1
4.8
1.3
1.4
mmol/l
2.72
257
2552
13
101
1.30
0.32
1.3
1.3
—
—
—
0
0
7
53
1.33
0.31
1.0
1.1
—
—
—
0
0
11
84
1.32
0.30
2.3
1.5
—
0.0
—
0
21
38
428
0.87
0.30
1.2
1.3
137.1
33.6
iu/ml
0.84
11
133
8
62
1.30
0.28
1.0
1.2
—
1.6
—
0
9
102
961
1.09
0.27
2.3
2.1
127.3
295.5
u/l
1.46
96
899
9
72
1.26
0.26
1.3
1.2
—
—
—
0
0
9
72
1.26
0.26
1.3
1.2
—
—
—
0
0
16
190
0.83
0.24
2.0
1.8
—
—
—
0
0
10
79
1.27
0.22
1.3
1.7
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
27.3
21.5
iu/l
—
5
34
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
4.7
—
138.4
—
0
13
0
13
0.00
0.21
0.0
1.5
—
68.6
—
0
13
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
13
150
0.86
0.15
1.9
1.4
—
—
—
0
0
11
126
0.87
0.11
1.4
1.8
44.1
43.2
nmol/l
0.04
11
119
5
46
1.09
0.09
1.0
1.2
—
—
—
0
0
34
351
0.97
0.03
1.9
2.3
12.0
13.0
nmol/l
0.37
29
309
79
783
1.01
0.01
6.1
4.0
0.1
0.0
estimate
0.49
36
254
16
154
1.04
0.00
1.2
1.4
—
42.2
—
0
11
66
666
0.99
0.00
1.9
1.8
468.5
7407834.4
pmol/l
0.50
53
540
12
115
1.05
0.00
10.8
3.3
4.0
4.0
mmol/l
0.04
12
103
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
101.5
—
0
6
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
26.3
—
0
5
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
1.3
—
0
6
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_KIDNEY_PAPILLARYADENO – Adenocarcinoma and Papillary adenocarcinoma of kidney
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).